DISPOSITION OF QUININE IN RATS WITH INDUCED RENAL-FAILURE

被引:0
|
作者
ONYEJI, CO
DIXON, PAF
UGWU, NC
机构
[1] OBAFEMI AWOLOWO UNIV,FAC PHARM,DEPT PHARMACOL,IFE,NIGERIA
[2] OBAFEMI AWOLOWO UNIV,FAC HLTH SCI,IFE,NIGERIA
关键词
CLEARANCE; KIDNEY FAILURE; METABOLITES; PHARMACOKINETICS; QUININE; RATS; LABORATORY;
D O I
10.1007/BF01962536
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aetiologically different models of experimental acute renal failure were induced in rats by the administration of glycerol, mercuric chloride and gentamicin, respectively, to different groups. Quinine levels in plasma and urine of the rats with induced renal failure were determined and pharmacokinetic parameters (elimination t1/2, CL(p), V, CL(R) AUC0-infinity) of the drug were derived and compared with values obtained from control rats following intraperitoneal administration of a 10 mg/kg body-weight dose of quinine. Results showed that each of the three compounds caused an up to 25-fold increase in the plasma levels of the drug and a marked decrease in the levels of the metabolite 3-hydroxyquinine. All the pharmacokinetic parameters determined for the rats with renal impairment were markedly different when compared to control. The high plasma quinine levels observed in the rats with renal failure' could be largely due to the marked decrease in V and reduced metabolism. Also, in the rats with renal impairment, no correlation was observed between the increased plasma urea levels and plasma quinine levels or disposition of the drug. The results of the study suggest that quinine should be used with caution in patients with renal impairment. The plasma urea levels, as a measure of renal function, might not provide a suitable index for determining quinine dosage.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 50 条
  • [1] DISPOSITION AND PHARMACOKINETICS OF PHENYTOIN IN RATS WITH ACUTE RENAL-FAILURE
    ALI, M
    LINDUP, WE
    BRITISH JOURNAL OF PHARMACOLOGY, 1979, 66 (03) : P487 - P487
  • [2] DISPOSITION OF DIGITOXIN IN RENAL-FAILURE
    VOHRINGER, HF
    RIETBROCK, N
    SPURNY, P
    KUHLMANN, J
    HAMPL, H
    BAETHKE, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1976, 19 (04) : 387 - 395
  • [3] PROPRANOLOL DISPOSITION IN RENAL-FAILURE
    WOOD, AJJ
    VESTAL, RE
    SPANNATH, C
    STONE, WJ
    WILKINSON, GR
    SHAND, DG
    CLINICAL RESEARCH, 1979, 27 (02): : A239 - A239
  • [4] PROPRANOLOL DISPOSITION IN RENAL-FAILURE
    WOOD, AJJ
    VESTAL, RE
    SPANNUTH, CL
    STONE, WJ
    WILKINSON, GR
    SHAND, DG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 (06) : 561 - 566
  • [5] ENCAINIDE DISPOSITION IN RENAL-FAILURE
    BERGSTRAND, RH
    WANG, T
    STONE, WJ
    WILKINSON, GR
    WOLTENDEN, HT
    RODEN, DM
    WOOSLEY, RL
    WOOD, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 182 - 182
  • [6] STUDIES ON THE DISPOSITION OF VERAPAMIL IN RENAL-FAILURE
    MOOY, J
    SCHOLS, M
    VANBAAK, M
    VANHOOFF, M
    RAHN, KH
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1984, 6 (04) : 175 - 175
  • [7] ENCAINIDE DISPOSITION IN PATIENTS WITH RENAL-FAILURE
    BERGSTRAND, RH
    WANG, T
    RODEN, DM
    STONE, WJ
    WOLFENDEN, HT
    WOOSLEY, RL
    WILKINSON, GR
    WOOD, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (01) : 64 - 70
  • [8] PROPAFENONE DISPOSITION IN RENAL-INSUFFICIENCY AND RENAL-FAILURE
    BURGESS, E
    DUFF, H
    WILKES, P
    JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (02): : 112 - 113
  • [9] RENAL OSTEODYSTROPHY IN RATS WITH SURGICALLY-INDUCED RENAL-FAILURE
    DANGELO, A
    BONUCCI, E
    FABRIS, A
    GIANNINI, S
    FERRARESE, P
    MALVASI, L
    MESSA, M
    MORBIATO, F
    VASSANELLI, P
    MASCHIO, G
    MINERAL AND ELECTROLYTE METABOLISM, 1983, 9 (03) : 166 - 166
  • [10] EFFECT OF EXPERIMENTAL RENAL-FAILURE ON THE DISPOSITION KINETICS OF L-PROPRANOLOL IN RATS
    TERAO, N
    SHEN, DD
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1983, 227 (02): : 295 - 301